Recent Financings Boost Biotech M&A Returns

A recent influx of venture capital does appear to place start-ups in an optimal position to negotiate better terms and receive a higher payment.

In the last five years, the average up-front return on investment in private biotech acquisitions has declined from 4x in 2006 to under 2x thus far in 2010, thanks primarily to the rise in earn-out-heavy dealmaking. ( See "Pharma: Serious About Change?" IN VIVO , October 2010 Also see "Pharma: Serious About Change? " - In Vivo, 1 October, 2010. and "Biotech Backers Are Learning to Live with Exit-by-Earn-out," START-UP , March 2010 Also see "Biotech Backers Are Learning to Live with Exit-by-Earn-out " - Scrip, 1 March, 2010..) While there have been a few outliers – Direvo Biotech AG and CoGenesys snatched 8x and 7x returns, respectively, when they were purchased by Bayer HealthCare LLC and Teva Pharmaceutical Industries Ltd. – more deals have trended like Wyeth's (now part of Pfizer Inc.) buy of Thiakis, which had raised $120 million in venture capital, only to be acquired for $30 million up front. [See Deal][See Deal][See Deal]

At a time when bigger pharmaceutical players have the dealmaking leverage, what steps – if any – can privately held...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Business

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.